Alcyone Therapeutics Inc., a biotechnology company specializing in advanced genetic therapies and delivery systems for complex neurological conditions, has announced that the U.S. Food and Drug Administration

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved DARZALEX FASPRO® in combination with bortezomib, lenalidomide, and dexamethasone for use as induction

Georgiamune Inc., a biotechnology company in its clinical stages, has announced the initiation of a Phase 1 trial involving their new drug, GIM-531. This study marks the first human dosing of GIM-531, an oral therapy

Novartis has announced that the FDA has granted Priority Review status to Scemblix® (asciminib) for treating newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukemia

Boehringer Ingelheim has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a new indication for SPEVIGO®

Shanghai Junshi Biosciences Co., Ltd., a prominent biopharmaceutical firm focused on innovation, along with its subsidiary TopAlliance Biosciences Inc., has received a positive opinion from the Committee for Medicinal Products

Checkpoint Therapeutics, Inc., a company specializing in immunotherapy and targeted oncology, has announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted Biologics License Application (BLA) for cosibelimab. This anti-PD-L1 antibody

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company focused on advancing cell therapies for AL Amyloidosis and autoimmune conditions, has received an $8 million CLIN2 grant from the California Institute for Regenerative Medicine

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in novel treatments for rare genetic skin disorders without FDA-approved options, has agreed to merge with Pieris Pharmaceuticals, Inc.

Annovis Bio Inc. has achieved a notable milestone with the issuance of a U.S. patent for its leading drug candidate, buntanetap, which is being investigated for the treatment of acute traumatic brain injuries